Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions (SKINDLE)

This study is currently recruiting participants.

Verified August 2012 by Rigel Pharmaceuticals

Sponsor:

Information provided by (Responsible Party):

Rigel Pharmaceuticals

ClinicalTrials.gov Identifier:

NCT01597050

First received: May 9, 2012

Last updated: August 17, 2012

Last verified: August 2012

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	October 2013
Estimated Primary Completion Date:	September 2013 (Final data collection date for primary outcome measure)